The Pharmacy and Poisons Board (PPB) has issued a public notice banning the trade, importation, and handling of unregistered health products and technologies in Kenya, citing concerns over safety and compliance.
In the notice, the Board emphasized its statutory mandate to protect public health by ensuring access to quality, safe, and affordable pharmaceuticals.
The regulator expressed concern over the increasing presence of unregistered pharmaceutical products in the market, particularly those referencing the Indian Pharmacopeia (IP), which does not meet Kenya’s drug registration standards.
The Board directed all stakeholders to:
1. Halt the trade, importation, or handling of unregistered products, including those referencing the Indian Pharmacopeia.
2. Ensure all pharmaceutical products in their possession are duly registered and approved by the PPB.
3. Adhere to the Pharmacy and Poisons Act and other relevant regulations.
Failure to comply will result in severe penalties, including the seizure of products, license revocation, and legal prosecution.
The PPB has pledged to intensify market surveillance and enforce compliance with the regulatory framework.
Stakeholders are encouraged to report non-compliance or seek clarification through official channels at info@ppb.go.ke, practice@ppb.go.ke, or tradeaffairs@ppb.go.ke.
The Board calls on all stakeholders to join hands in safeguarding the health and safety of Kenyans.
